We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » cGMP Vigilance Needed When Working With Chinese Firms, Expert Says
cGMP Vigilance Needed When Working With Chinese Firms, Expert Says
March 22, 2005
U.S. generics firms looking to lower drug-development costs by contracting with Chinese drugmakers for active pharmaceutical ingredients (APIs) need to do so carefully, according to an industry expert, who warned that such partnerships are not always cost-effective.